Cryopyrin-associated periodic syndromes (CAPS) are a family of related conditions associated with heterozygous mutations in NLRP3 (formerly CIAS1), the gene that encodes the NACHT, LRR and PYD ...
On February 27, 2008, the Tarrytown, New York-based Regeneron Pharmaceuticals received approval for Arcalyst (rilonacept), a treatment for cryopyrin-associated periodic syndromes (CAPS), including ...
Insight 数据库显示,利纳西普早在 2008 年就获得美国 FDA 批准上市,商品名为 ARCALYST®,用于治疗 冷吡啉相关的周期性综合征 (CAPS),包括家族性寒冷型自身炎症综合征 (FCAS)和穆-韦二氏综合征 (MWS);2020 ...
This medication is an interleukin-1 beta-blocker, prescribed for auto-inflammatory diseases known as cryopyrin-associated periodic syndrome (CAPS). It decreases interleukin-1 beta's activity.
VPM087 is an anti-interleukin-1 beta antibody, hitting the same target as Novartis’ canakinumab, which is already approved as Ilaris for cryopyrin-associated periodic syndromes and systemic ...